miR 125a and miR 34a expression predicts Richter syndrome in chronic lymphocytic leukemia patients.
Chronic lymphocytic leukemia (CLL) is the most common adult leukemia. It is characterized by the accumulation of CD19+/CD5+ lymphocytes and can have variable outcomes. Richter syndrome (RS) is a lethal complication in CLL patients that results in aggressive B cell lymphomas, and there are no tests to predict its occurrence. Because alterations in microRNA expression can predict the development and progression of several cancers, we investigated whether dysregulation of specific microRNAs can predict RS in CLL patients. Thus, we compared microRNA expression levels in samples from 49 CLL patients who later developed RS with samples from 59 CLL patients who did not. We found that high expression of miR 125a 5p or low expression of miR 34a 5p can predict ~50% of RS with a false positive rate of ~9% We found that CLL patients predicted to develop RS show either an increase of miR 125a 5p expression ~20 fold) or a decrease of miR 34a 5p expression ~21 fold) compared with CLL patients that are not predicted to develop RS. Thus, miR 125a 5p and miR 34a 5p can be valuable predictor markers of RS and have the potential to provide physicians with information that can indicate the best therapeutic strategy for CLL patients.
Blood